Betrixaban enters Phase III trial for prevention of VTE- Portola Pharma
Portola Pharmaceuticals has completed patient enrollment in the pivotal Phase III APEX (Acute Medically Ill VTE Prevention with Extended Duration Betrixaban) Study. The 7,500-patient study is evaluating betrixaban, an investigational oral, once-daily Factor Xa inhibitor anticoagulant, for extended-duration prevention of venous thromboembolism (VTE), or blood clots, in acute medically ill patients. These are patients who are hospitalized for serious medical conditions, such as heart failure, stroke, infection and pulmonary disease. Portola plans to report top-line data at the end of the first quarter of 2016.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.